Convert Pharmaceuticals is a drug development company building a proprietary drug pipeline exploiting tumour hypoxia for therapeutic benefit. Convert’s lead product, CP-506 is a hypoxia activated prodrug - HAP. The company combines proprietary insights in the tumour hypoxia with expertise in drug and biomarker development to develop effective and well-tolerated HAPs. Convert has an ongoing phase I-IIa trial, is supported by the EIC (€2.5M), and has acquired the IP of an additional HAP.